This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Ascendis fires back at USITC complaint with suit seeking noninfringement declaration

( April 15, 2025, 15:51 GMT | Official Statement) -- MLex Summary: Ascendis Pharma sued rival BioMarin Pharmaceutical in the US Northern District of California, seeking a declaration of noninfringement for BioMarin’s C-type natriuretic peptides patent. BioMarin filed a complaint with the US International Trade Commission early this month accusing Ascendis and Wacker Pharmaceutical of importing illegal quantities of a generic product into the US in preparation for FDA approval of a rival drug to BioMarin’s Voxzogo. Ascendis argued in its suit that it's protected by the safe harbor protecting the importation of small quantities of a drug for use in the Food and Drug Administration approval process. See complaint attached....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections